Why the study?
The study was conducted to evaluate plasma and cerebrospinal fluid nimodipine concentrations in patients with aneurysmal subarachnoid hemorrhage and their correlation with clinical outcome.
Do cerebrospinal fluid concentrations of nimodipine correlate with long-term clinical outcome in patients with aneurysmal subarachnoid hemorrhage?
Comparison
Nimodipine infusion evaluated for plasma and CSF concentrations
Design
Pilot study
Follow-up
9 months
Key result
Higher cerebrospinal fluid nimodipine concentrations were significantly associated with no significant disability at 9 months in patients with aneurysmal subarachnoid hemorrhage (P=0.015).
Authors
Loading...
Should not yet guide nimodipine dosing in aSAH; hypothesis-generating for CSF-targeted delivery.
Observational (n=23)
Do cerebrospinal fluid concentrations of nimodipine correlate with long-term clinical outcome in patients with aneurysmal subarachnoid hemorrhage?
p-value: p=0.015
CSF nimodipine concentrations, but not arterial concentrations or doses, correlate with long-term clinical outcomes in patients with aneurysmal subarachnoid hemorrhage.
Riva et al. (2019) conducted an observational in Aneurysmal subarachnoid hemorrhage (n=23). Cerebrospinal fluid nimodipine concentrations vs. Lower concentrations was evaluated on Clinical outcome assessed at 9 months by the modified Rankin scale (p=0.015). Higher cerebrospinal fluid nimodipine concentrations were significantly associated with no significant disability at 9 months in patients with aneurysmal subarachnoid hemorrhage (P=0.015).